<DOC>
	<DOCNO>NCT00840515</DOCNO>
	<brief_summary>A phase 2 double blind randomise study PraevoSkin , melatonin contain emulsion , prevention radiation induce dermatitis .</brief_summary>
	<brief_title>PraevoSkin Emulsion Prevention Radiation Induced Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<criteria>1 . Female patient least 18 year unilateral breast cancer follow lumpectomy +/ chemotherapy . 2 . Planned receive 50 Gy whole breast irradiation +/ boost tumor bed . 3 . ECOG PERFORMANCE STATUS 01 . 4 . Capable give write informed consent follow instruction apply study emulsion placebo per control . 5 . No comorbidities know affect radiotherapy reaction . 6 . No coexist acute chronic skin disease . 7 . No evidence infection inflammation breast treat . 8 . Not receive chemotherapy radiotherapy course.Biological therapy ( e.g . Herceptin ) hormone therapy allow study . 1 . Chemotherapy within 4 week prior plan start radiation chemotherapy plan radiation . 2 . Prior radiotherapy site . 3 . Collagen vascular disease . 4 . Diabetes mellitus require medication . 5 . Uncontrolled hypertension . 6 . Participation clinical study . 7 . Any contraindicate treatment Melatonin . 8 . History allergy peanut fragrance . 9 . History severe allergic reaction ( e.g . asthma ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>